Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Editor—Two breast cancer susceptibility genes, BRCA1 and BRCA2, have been identified.1-3 Combined, these large and complex genes have over 800 reported genetic variants. More than 50 variants occurring within the introns of these genes are known. The clinical significance of these intronic variants, which could potentially impact RNA splicing, is largely undetermined.4-7
A variant within intron 20 of BRCA1 occurs through the duplication of 12 base pairs (bp) (GTATTCCACTCC) 48 bp from the donor junction. This variant has been observed in patients from cancer families.8-10 Furthermore, biochemical analysis showed the loss of contribution by one chromosome to the normal RNA in a breast cancer patient with IVS20ins12.11 This was shown by sequencing cDNA which showed the loss of a heterozygous base at the silent polymorphism at codon 1436 (serine TCT or TCC). These authors concluded that IVS20ins12 could represent a clinically significant regulatory mutation, although this variant was also present in a control specimen. More recently, IVS20ins12 was reported in four controls (with varying family histories of cancer, but otherwise healthy) and one early onset breast/ovarian cancer patient in a Polish BRCA1 study.12 No aberrant splicing products were detected in these samples, but mRNA abundance and possible loss of transcript have not been assayed. These authors concluded that the issue merits a more extensive study.
Here, a patient diagnosed with breast cancer at the age of 40 and with cancer reported on the maternal side of her family is described. Clinical full sequence analysis of BRCA1 and BRCA2 (BRACAnalysis, Myriad Genetic Laboratories, Salt Lake City, UT) identified IVS20ins12, as well as common single nucleotide polymorphisms (SNPs), particularly S1613G (AGT for serine and GGT for glycine). The patient was counselled regarding the uncertain clinical significance of this variant and elected to participate in this research analysis.
cDNA was synthesised from RNA isolated from peripheral blood mononuclear cells from both the patient and a control sample that also contained S1613G. PCR reactions generated fragments spanning S1613G to exon 21. These products were separated by agarose gel electrophoresis and fragments corresponding in size to the normal transcript were isolated. No notable bands that might represent alternative/aberrant splice products were observed in either sample. The isolated fragments served as targets in subsequent PCR reactions designed to evaluate the sequence at either the polymorphism or the exon junctions. DNA sequencing clearly shows a heterozygous base at codon 1613 (fig 1A) and normal RNA splice junctions for exons 18-21 (fig 1B), indicating that both chromosomes contribute to normally spliced transcripts.
In seeming contrast to our analysis, Robledo et al 11 observed loss of transcript in an IVS20ins12 carrier. In patient RNA, only the sequence TCC was detected at codon 1436; RNA from the consensus (TCT) allele was lost. The question remained whether the lost allele came from the same chromosome that also contained IVS20ins12. A single nucleotide polymorphism haplotype analysis of patient samples addressed this question.
Our anonymised BRCA1 sequence variation database contained 19 observations of IVS20ins12 and they all shared SNP haplotype 2 (fig 2). There were six homozygous haplotype 2 carriers. The rest contained a haplotype 2 chromosome along with a chromosome with one of the five other previously described common haplotypes. Therefore, IVS20ins12 is found solely on a haplotype 2 background. This finding agrees with the previous observation that the vast majority of infrequent sequence variations within the BRCA1 gene are only found on a single SNP haplotype background.13 14 Indeed, given that this population includes 3550 subjects who do not have a single copy of haplotype 2, and none of these carries an insertion in IVS20, there is 90% confidence that the frequency of IVS20ins12 on non-haplotype 2 backgrounds does not exceed 0.033%. In contrast, 0.77% of 2452 instances of haplotype 2 carry IVS20ins12. Since IVS20ins12 is present on the background of haplotype 2, for which codon 1436 is encoded by TCC, the RNA detected by Robledo et al 11 was transcribed from the chromosome carrying the insertion. It appears that the loss of transcript resulted from a hitherto unidentified BRCA1 mutation on the other chromosome.
These data and analyses strongly suggest that BRCA1 IVS20ins12 is a polymorphism with no obvious clinical significance. Biochemical evaluation of RNA encoding BRCA1 from a patient carrying the variant shows that both chromosomes contribute to the normally spliced transcript. Although these transcripts were isolated from leucocytes, it is highly unlikely that tissue specific splicing events would create mutant transcripts. This conclusion is augmented by the clarification of a seemingly conflicting result. Here, genetic analysis showed the presence of IVS20ins12 on the only functional copy of the BRCA1 gene in a previously described carrier of a loss of transcript mutation.11